OBJECTIVE: Psychotropic medication nonadherence is a major public health problem, but few studies have focused on Latinos. The authors systematically reviewed the literature on rates of and factors influencing antipsychotic, antidepressant, and mood stabilizer nonadherence among U.S. Latinos. METHODS: MEDLINE and PsycINFO were searched by using the keywords adherence, compliance, Latino, Hispanic, psychotropic, and related terms; bibliographies from relevant reviews and studies were also searched. Twenty-one studies met inclusion criteria: published since 1980 in English or Spanish and measured psychotropic medication nonadherence rates among U.S. Latino adults. Information was extracted about study design and objective, location, population, medication type, participant demographic characteristics, adherence measures, adherence rates, and factors related to adherence. RESULTS: In the 17 studies that included Latinos and other minority groups, mean nonadherence rates were 41%, 31%, and 43%, respectively, among Latinos, Euro-Americans, and African Americans, with an overall effect size of .64 between Latinos and Euro-Americans. In the four studies that included only Latinos, the mean nonadherence rate was 44%. Ten of 16 studies found that Latinos had significantly lower adherence rates than Euro-Americans. Risk factors for nonadherence included being a monolingual Spanish speaker, lacking health insurance, experiencing access barriers to high-quality care, and having lower socioeconomic status. Protective factors included family support and psychotherapy. CONCLUSIONS: Rates of nonadherence to psychotropic medications were found to be higher for Latinos than for Euro-Americans. Further investigation is needed to understand the potentially modifiable individual and society-level mechanisms of this discrepancy. Clinical and research interventions to improve adherence should be culturally appropriate and incorporate identified factors.
OBJECTIVE: Psychotropic medication nonadherence is a major public health problem, but few studies have focused on Latinos. The authors systematically reviewed the literature on rates of and factors influencing antipsychotic, antidepressant, and mood stabilizer nonadherence among U.S. Latinos. METHODS: MEDLINE and PsycINFO were searched by using the keywords adherence, compliance, Latino, Hispanic, psychotropic, and related terms; bibliographies from relevant reviews and studies were also searched. Twenty-one studies met inclusion criteria: published since 1980 in English or Spanish and measured psychotropic medication nonadherence rates among U.S. Latino adults. Information was extracted about study design and objective, location, population, medication type, participant demographic characteristics, adherence measures, adherence rates, and factors related to adherence. RESULTS: In the 17 studies that included Latinos and other minority groups, mean nonadherence rates were 41%, 31%, and 43%, respectively, among Latinos, Euro-Americans, and African Americans, with an overall effect size of .64 between Latinos and Euro-Americans. In the four studies that included only Latinos, the mean nonadherence rate was 44%. Ten of 16 studies found that Latinos had significantly lower adherence rates than Euro-Americans. Risk factors for nonadherence included being a monolingual Spanish speaker, lacking health insurance, experiencing access barriers to high-quality care, and having lower socioeconomic status. Protective factors included family support and psychotherapy. CONCLUSIONS: Rates of nonadherence to psychotropic medications were found to be higher for Latinos than for Euro-Americans. Further investigation is needed to understand the potentially modifiable individual and society-level mechanisms of this discrepancy. Clinical and research interventions to improve adherence should be culturally appropriate and incorporate identified factors.
Authors: Jonathan P Lacro; Laura B Dunn; Christian R Dolder; Susan G Leckband; Dilip V Jeste Journal: J Clin Psychiatry Date: 2002-10 Impact factor: 4.384
Authors: Lisa A Cooper; Junius J Gonzales; Joseph J Gallo; Kathryn M Rost; Lisa S Meredith; Lisa V Rubenstein; Nae-Yuh Wang; Daniel E Ford Journal: Med Care Date: 2003-04 Impact factor: 2.983
Authors: Concepcion Barrio; Ann Marie Yamada; Hazel Atuel; Richard L Hough; Simon Yee; Bryan Berthot; Patricia A Russo Journal: Schizophr Res Date: 2003-04-01 Impact factor: 4.939
Authors: Benedetto Vitiello; M Audrey Burnam; Eric G Bing; Robin Beckman; Martin F Shapiro Journal: Am J Psychiatry Date: 2003-03 Impact factor: 18.112
Authors: John R Geddes; Stuart M Carney; Christina Davies; Toshiaki A Furukawa; David J Kupfer; Ellen Frank; Guy M Goodwin Journal: Lancet Date: 2003-02-22 Impact factor: 79.321
Authors: Jeanne Miranda; Naihua Duan; Cathy Sherbourne; Michael Schoenbaum; Isabel Lagomasino; Maga Jackson-Triche; Kenneth B Wells Journal: Health Serv Res Date: 2003-04 Impact factor: 3.402
Authors: Patrick W Corrigan; Dana J Kraus; Susan A Pickett; Annie Schmidt; Ed Stellon; Erin Hantke; Juana Lorena Lara Journal: Psychiatr Serv Date: 2017-01-17 Impact factor: 3.084
Authors: Victoria B Mitrani; Brian E McCabe; Rosa M Gonzalez-Guarda; Aubrey Florom-Smith; Nilda Peragallo Journal: West J Nurs Res Date: 2013-03-14 Impact factor: 1.967
Authors: Alisa B Busch; Haiden A Huskamp; Brian Neelon; Tim Manning; Sharon-Lise T Normand; Thomas G McGuire Journal: Med Care Date: 2009-12 Impact factor: 2.983